Subscribe: Market Wire - Medical and Healthcare: Healthcare
http://img.marketwire.com/rss/mwMHHE.rss
Preview: Market Wire - Medical and Healthcare: Healthcare

Marketwired - Healthcare



Marketwired - Healthcare



Last Build Date: Fri, 15 Dec 2017 08:32:03 EST

Copyright: Copyright: (C) Marketwired
 



IntelGenx Receives Health Canada Clearance to Begin Phase 2a Study with Montelukast Versafilm(TM) in Mild to Moderate Alzheimer's Disease

Fri, 15 Dec 2017 08:00:00 EST

SAINT-LAURENT, QUEBEC--(Marketwired - Dec. 15, 2017) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) (the "Company" or "IntelGenx") is pleased to announce that Health Canada has cleared the clinical trial application for its Montelukast VersaFilmT intended for the treatment of mild to moderate Alzheimer's disease ("AD"). The phase 2a proof of concept ("POC") clinical study will start screening AD patients in Q1 2018.




Three Key Ways ICH E6 (R2) Impacts Study Oversight, New Webinar Hosted by Xtalks

Fri, 15 Dec 2017 07:30:00 EST

The presentation taking place on January 17, 2018 will take a detailed look at the interactions and performance of sponsor-CRO driven studies




UCL Nears Completion of OTC Listing Upgrade

Thu, 14 Dec 2017 13:37:46 EST

Company Provides Shareholder Update




Effective Implementation of the Revised EMA First-into-Human (FIH) Guidance to Accelerate Your Early Clinical Development, New Webinar Hosted by Xtalks

Thu, 14 Dec 2017 07:30:00 EST

TORONTO, ON--(Marketwired - December 14, 2017) - In this webinar speakers from Simbec Research will discuss the use of integrated protocols (umbrella protocols) to maximise programme efficiency.




NanoVibronix Announces IMS Ultrasound (UK) Ltd as its Exclusive UK Distributor for UroShield(TM) Following Successful Interim Trial Results

Thu, 14 Dec 2017 07:30:00 EST

UroShield(TM) Designed to Save Lives Due to High Rate of Catheter-Associated Urinary Tract Infections in the UK

IMS Ultrasound Agrees to Fund Additional Clinical Study with UK's National Health Service




Vernalis PLC: AGM Statement

Thu, 14 Dec 2017 02:00:00 EST

WINNERSH, UNITED KINGDOM--(Marketwired - Dec 14, 2017) - Vernalis PLC (LSE: VER)




Tetra Bio-Pharma Reinforces its Development Program by Signing Research & Development Agreement with Constance Therapeutics and Receiving Financial Support from NSERC

Wed, 13 Dec 2017 17:17:33 EST

OTTAWA, ONTARIO--(Marketwired - Dec. 13, 2017) - Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that the company has signed an exclusive research and development (R&D) agreement with Constance Therapeutics for the pharmaceutical drug development, and eventual commercialization in Canada, of their standardized, patent-pending, medicinal cannabis extract products. In addition to this agreement, the Company further strengthens its R&D program by means of a National Sciences and Engineering Research Council of Canada (NSERC) grant in its collaborative project with Dr Stan Kubow at McGill university.




La gouverneure générale octroie une distinction honorifique pour avoir offert aux adolescents le pouvoir de sauver des vies

Wed, 13 Dec 2017 12:11:12 EST

OTTAWA, ON--(Marketwired - 13 décembre 2017) - La gouverneure générale, Julie Payette, a présenté la prestigieuse Croix du service méritoire à la directrice et fondatrice de la Fondation ACT, Sandra Clarke, et au Directeur médical d'ACT et Urgentologue de l'Hôpital d'Ottawa, Dr Justin Maloney, au cours d'une cérémonie tenue au Rideau Hall le 12 décembre dernier. Cette distinction honore Mme Clarke et Dr Maloney pour la création et l'intégration du Programme de RCR au secondaire d'ACT (La Fondation des soins avancés en urgence coronarienne du Canada).




Governor General Presents Meritorious Service Cross for Empowering Teens to Save Lives

Wed, 13 Dec 2017 11:57:01 EST

OTTAWA, ON--(Marketwired - December 13, 2017) - Governor General Julie Payette presented the prestigious Governor General's Meritorious Service Cross to ACT Foundation Executive Director and Founder, Sandra Clarke, and ACT's Medical Director and Ottawa Hospital Emergency Physician, Dr. Justin Maloney at a Rideau Hall ceremony on December 12. The Award honours Ms. Clarke and Dr. Maloney for their ground-breaking establishment of the ACT (Advanced Coronary Treatment) High School CPR Program.




Optimize Patient Enrollment by Incorporating Physician Referral Networks in Your Outreach Plan, New Webinar Hosted by Xtalks

Wed, 13 Dec 2017 07:30:00 EST

TORONTO, ON--(Marketwired - December 13, 2017) - In a webinar upcoming on Tuesday, January 9, 2018, a panel of physicians and clinical site experts will discuss the various clinical trial stakeholders and the traditional interactions they have with referring physicians. They will share how these efforts can meet their full potential by leveraging proven referring physician outreach models and the key tactics within those.




Vernalis + Daiichi Sankyo Enter Collaboration

Wed, 13 Dec 2017 02:00:00 EST

WINNERSH, UNITED KINGDOM--(Marketwired - Dec 13, 2017) - Vernalis PLC (LSE: VER)




Milestone Scientific Participates in the 2017 Greater New York Dental Meeting

Tue, 12 Dec 2017 07:30:00 EST

Discusses Potential Role of New Cosmetic Botox Injection Technology in Dental Practices




Rennova Health Announces an Upgrade of MedicalMime's Flagship EHR M2Select to Version 3.3

Mon, 11 Dec 2017 09:20:00 EST

WEST PALM BEACH, FL--(Marketwired - December 11, 2017) - Rennova Health, Inc. (OTCQB: RNVA) (OTCQB: RNVAW) ("Rennova" or the "Company"), a vertically integrated provider of industry-leading diagnostics and supportive software solutions to healthcare providers that opened its first rural hospital in Oneida, Tenn. on August 8, 2017, announces an upgrade of its flagship electronic health records (EHR) platform, M2Select to Version 3.3. This platform is available to office-based physicians, as well as to mental health providers working in substance abuse and drug and alcohol rehabilitation facilities.




Rising Overdose Deaths in Orange County Prompt New Addiction Treatment Center to Open

Mon, 11 Dec 2017 09:00:00 EST

CleanSlate Combating Tragic Rates of Opioid Dependency in Infants by Increasing Access to Treatment, Fast-Tracking Expectant Moms




IntelGenx Receives USPTO Notice of Allowance for Montelukast Orange Book Eligible Patent

Mon, 11 Dec 2017 08:00:00 EST

SAINT-LAURENT, QUEBEC--(Marketwired - Dec. 11, 2017) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT) ("IntelGenx"), a leading oral drug delivery company primarily focused on the development and manufacturing of innovative pharmaceutical oral films based on its proprietary VersaFilmT technology platform, today announced that the United States Patent and Trademark Office ("USPTO") has granted a Notice of Allowance for US Patent Application 15/299,054, entitled "Device and Method of Treating Conditions Associated with Neuroinflammation." This film formulation patent covers Montelukast oral film formulations designed for the treatment of neuroinflammation and is intended to protect IntelGenx' Montelukast VersaFilmT product.




Aequus announces the issuance of stock options

Fri, 08 Dec 2017 20:04:14 EST

VANCOUVER, BC--(Marketwired - December 08, 2017) - Aequus Pharmaceuticals Inc. (TSX VENTURE: AQS) (OTCQB: AQSZF) ("Aequus" or the "Company"), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, today announced the issuance of stock options to directors, officers, staff and consultants. The stock options give the holders the right to purchase up to an aggregate of 2,302,941 common shares of the Company. These stock options are exercisable at a price of $0.195 per share, for a term of eight years, and vest in tranches over 2 to 3 year periods. The terms of the stock options granted on December 7, 2017 are in accordance with the Company's Stock Option Plan.